A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

Inclusion Criteria:

• Newly diagnosed MAC-PD (primary or recurrent) as per the international NTM guidelinethat requires three-drug antimycobacterial treatment

• Signed and dated informed consent

Exclusion Criteria:

• The participant is in poor general condition where participation in the study cannotbe accepted per discretion of the Investigator

• The participant has a known or suspected, current drug or alcohol abuse, that is, inthe opinion of the Investigator, sufficient to compromise the safety or cooperationof the patient

• HIV-infection;

• Cystic fibrosis;

• >1 month antibiotic treatment for current MAC infection;

• < 6 months between previous antimycobacterial NTM-PD treatment and antimycobacterialtreatment for current MAC-PD

• Disseminated MAC infection;

• Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment;

• Active pulmonary malignancy (primary or metastatic) or any other malignancyrequiring chemotherapy or radiotherapy within 6 months before screening oranticipated during the study period;